Albumin-based drug delivery systems:
Albumin is playing an increasing role as a versatile, biodegradable drug carrier in clinical theranostics. By applying different techniques, smart drug-delivery systems can be developed from albumin in order to improve drug delivery of different active pharmaceutical ingredients, even small-molecule...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
[2022]
|
| Schlagworte: | |
| Online-Zugang: | Volltext Volltext |
| Zusammenfassung: | Albumin is playing an increasing role as a versatile, biodegradable drug carrier in clinical theranostics. By applying different techniques, smart drug-delivery systems can be developed from albumin in order to improve drug delivery of different active pharmaceutical ingredients, even small-molecule drugs, peptides or enzymes. Principally, three drug delivery technologies can be distinguished for binding small-molecule or peptide drugs through the charged amino acids, carboxyl, and amino groups of albumin: physical or covalent binding of the drug to albumin through a ligand- or protein-binding group, the fusion of drug with albumin or the encapsulation of drugs into albumin nanoparticles. The accumulation of albumin in inflamed tissues and solid tumours forms the rationale for developing albumin-based drug delivery systems for targeted drug delivery. Besides tumour therapy, albumin-based drug delivery systems can be successfully applied as anti-inflammatory and anti-thrombotic coating for medical devices. The development and optimization of albumin nanoparticles may also be a rational and promising tool for conventional or alternative administration routes in order to improve therapy. This collection provides an overview of the significant scientific research works in this field, which may inspire researchers towards further development and utilization of these smart drug delivery systems. |
| Beschreibung: | Titelrückseite: This is a reprint of articles from the Special Issue published online in the open access journal Pharmaceutics (ISSN 1999-4923) (available at: www.mdpi.com/journal/pharmaceutics/special_issues/albumin_DDS). |
| Beschreibung: | 1 Online-Ressource (ix, 149 Seiten) |
| ISBN: | 9783036541075 |
| DOI: | 10.3390/books978-3-0365-4107-5 |
Internformat
MARC
| LEADER | 00000nam a22000001c 4500 | ||
|---|---|---|---|
| 001 | BV048447842 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220830s2022 xx o|||| 00||| eng d | ||
| 020 | |a 9783036541075 |9 978-3-0365-4107-5 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-4107-5 |2 doi | |
| 035 | |a (OCoLC)1344241051 | ||
| 035 | |a (DE-599)HEB497483750 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 |a DE-210 |a DE-521 |a DE-1102 |a DE-1046 |a DE-1028 |a DE-1050 |a DE-573 |a DE-M347 |a DE-92 |a DE-1051 |a DE-898 |a DE-859 |a DE-860 |a DE-1049 |a DE-861 |a DE-863 |a DE-862 |a DE-Re13 |a DE-Y3 |a DE-255 |a DE-Y7 |a DE-Y2 |a DE-70 |a DE-2174 |a DE-127 |a DE-22 |a DE-155 |a DE-91 |a DE-384 |a DE-473 |a DE-19 |a DE-355 |a DE-703 |a DE-20 |a DE-706 |a DE-824 |a DE-29 |a DE-739 | ||
| 084 | |a VX 8560 |0 (DE-625)147831:253 |2 rvk | ||
| 245 | 1 | 0 | |a Albumin-based drug delivery systems |c editor Gáabor Katona |
| 264 | 1 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c [2022] | |
| 264 | 2 | |a The Hague |b OAPEN FOUNDATION | |
| 264 | 4 | |c © 2022 | |
| 300 | |a 1 Online-Ressource (ix, 149 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Titelrückseite: This is a reprint of articles from the Special Issue published online in the open access journal Pharmaceutics (ISSN 1999-4923) (available at: www.mdpi.com/journal/pharmaceutics/special_issues/albumin_DDS). | ||
| 520 | 3 | |a Albumin is playing an increasing role as a versatile, biodegradable drug carrier in clinical theranostics. By applying different techniques, smart drug-delivery systems can be developed from albumin in order to improve drug delivery of different active pharmaceutical ingredients, even small-molecule drugs, peptides or enzymes. Principally, three drug delivery technologies can be distinguished for binding small-molecule or peptide drugs through the charged amino acids, carboxyl, and amino groups of albumin: physical or covalent binding of the drug to albumin through a ligand- or protein-binding group, the fusion of drug with albumin or the encapsulation of drugs into albumin nanoparticles. The accumulation of albumin in inflamed tissues and solid tumours forms the rationale for developing albumin-based drug delivery systems for targeted drug delivery. Besides tumour therapy, albumin-based drug delivery systems can be successfully applied as anti-inflammatory and anti-thrombotic coating for medical devices. The development and optimization of albumin nanoparticles may also be a rational and promising tool for conventional or alternative administration routes in order to improve therapy. This collection provides an overview of the significant scientific research works in this field, which may inspire researchers towards further development and utilization of these smart drug delivery systems. | |
| 650 | 0 | 7 | |a Albumine |0 (DE-588)4001090-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Wirkstofffreisetzung |0 (DE-588)4190018-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapeutisches System |0 (DE-588)4267580-7 |2 gnd |9 rswk-swf |
| 653 | |a plasma half-life extension | ||
| 653 | |a albumin conjugation | ||
| 653 | |a in vivo glucose-lowering activity | ||
| 653 | |a glucagon-like peptide-1 | ||
| 653 | |a quality by design | ||
| 653 | |a rapid equilibrium dialysis | ||
| 653 | |a muco-adhesion | ||
| 653 | |a brain PAMPA | ||
| 653 | |a RPMI 2650 nasal epithelial cell | ||
| 653 | |a human serum albumin | ||
| 653 | |a dimerization | ||
| 653 | |a doxorubicin | ||
| 653 | |a enhanced permeability and retention effect | ||
| 653 | |a antitumor | ||
| 653 | |a Arthrobacter globiformis | ||
| 653 | |a gout | ||
| 653 | |a half-life extension | ||
| 653 | |a inverse electron demand Diels-Alder reaction | ||
| 653 | |a site-specific albumin conjugation | ||
| 653 | |a thermostability | ||
| 653 | |a urate oxidase | ||
| 653 | |a albumin | ||
| 653 | |a anti-thrombotic | ||
| 653 | |a CD39 | ||
| 653 | |a coating of medical devices | ||
| 653 | |a stent coating | ||
| 653 | |a therapeutic fusion protein | ||
| 653 | |a conjugates | ||
| 653 | |a vanadium | ||
| 653 | |a cancer | ||
| 653 | |a prodrug | ||
| 653 | |a hydrogels | ||
| 653 | |a EPR/ESR spectroscopy | ||
| 653 | |a release behavior | ||
| 653 | |a disulfide | ||
| 653 | |a glioma | ||
| 653 | |a conjugate | ||
| 653 | |a albumin binding moieties | ||
| 653 | |a peptides | ||
| 653 | |a Evans blue | ||
| 653 | |a butyric acid | ||
| 653 | |a integrin αvβ6 | ||
| 653 | |a integrin αvβ6 binding peptide | ||
| 653 | |a improved pharmacokinetics | ||
| 653 | |a PET imaging | ||
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Albumine |0 (DE-588)4001090-9 |D s |
| 689 | 0 | 1 | |a Wirkstofffreisetzung |0 (DE-588)4190018-2 |D s |
| 689 | 0 | 2 | |a Therapeutisches System |0 (DE-588)4267580-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Katona, Gábor |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-3-0365-4108-2 |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/84432 |x Verlag |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.3390/books978-3-0365-4107-5 |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ZDB-94-OAB | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-033826048 | |
Datensatz im Suchindex
| _version_ | 1822082594161819648 |
|---|---|
| adam_text | |
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author2 | Katona, Gábor |
| author2_role | edt |
| author2_variant | g k gk |
| author_facet | Katona, Gábor |
| building | Verbundindex |
| bvnumber | BV048447842 |
| classification_rvk | VX 8560 |
| collection | ZDB-94-OAB |
| ctrlnum | (OCoLC)1344241051 (DE-599)HEB497483750 |
| discipline | Chemie / Pharmazie |
| discipline_str_mv | Chemie / Pharmazie |
| doi_str_mv | 10.3390/books978-3-0365-4107-5 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a22000001c 4500</leader><controlfield tag="001">BV048447842</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220830s2022 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783036541075</subfield><subfield code="9">978-3-0365-4107-5</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/books978-3-0365-4107-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1344241051</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)HEB497483750</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-210</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-1102</subfield><subfield code="a">DE-1046</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-1050</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-M347</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-1051</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-859</subfield><subfield code="a">DE-860</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-863</subfield><subfield code="a">DE-862</subfield><subfield code="a">DE-Re13</subfield><subfield code="a">DE-Y3</subfield><subfield code="a">DE-255</subfield><subfield code="a">DE-Y7</subfield><subfield code="a">DE-Y2</subfield><subfield code="a">DE-70</subfield><subfield code="a">DE-2174</subfield><subfield code="a">DE-127</subfield><subfield code="a">DE-22</subfield><subfield code="a">DE-155</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-384</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-703</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-706</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VX 8560</subfield><subfield code="0">(DE-625)147831:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Albumin-based drug delivery systems</subfield><subfield code="c">editor Gáabor Katona</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">[2022]</subfield></datafield><datafield tag="264" ind1=" " ind2="2"><subfield code="a">The Hague</subfield><subfield code="b">OAPEN FOUNDATION</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (ix, 149 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Titelrückseite: This is a reprint of articles from the Special Issue published online in the open access journal Pharmaceutics (ISSN 1999-4923) (available at: www.mdpi.com/journal/pharmaceutics/special_issues/albumin_DDS).</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">Albumin is playing an increasing role as a versatile, biodegradable drug carrier in clinical theranostics. By applying different techniques, smart drug-delivery systems can be developed from albumin in order to improve drug delivery of different active pharmaceutical ingredients, even small-molecule drugs, peptides or enzymes. Principally, three drug delivery technologies can be distinguished for binding small-molecule or peptide drugs through the charged amino acids, carboxyl, and amino groups of albumin: physical or covalent binding of the drug to albumin through a ligand- or protein-binding group, the fusion of drug with albumin or the encapsulation of drugs into albumin nanoparticles. The accumulation of albumin in inflamed tissues and solid tumours forms the rationale for developing albumin-based drug delivery systems for targeted drug delivery. Besides tumour therapy, albumin-based drug delivery systems can be successfully applied as anti-inflammatory and anti-thrombotic coating for medical devices. The development and optimization of albumin nanoparticles may also be a rational and promising tool for conventional or alternative administration routes in order to improve therapy. This collection provides an overview of the significant scientific research works in this field, which may inspire researchers towards further development and utilization of these smart drug delivery systems.</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Albumine</subfield><subfield code="0">(DE-588)4001090-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Wirkstofffreisetzung</subfield><subfield code="0">(DE-588)4190018-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapeutisches System</subfield><subfield code="0">(DE-588)4267580-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">plasma half-life extension</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">albumin conjugation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vivo glucose-lowering activity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glucagon-like peptide-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">quality by design</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rapid equilibrium dialysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">muco-adhesion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">brain PAMPA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RPMI 2650 nasal epithelial cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human serum albumin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dimerization</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">doxorubicin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">enhanced permeability and retention effect</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antitumor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Arthrobacter globiformis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gout</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">half-life extension</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inverse electron demand Diels-Alder reaction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">site-specific albumin conjugation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">thermostability</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urate oxidase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">albumin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-thrombotic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CD39</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">coating of medical devices</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stent coating</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapeutic fusion protein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">conjugates</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vanadium</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prodrug</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hydrogels</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EPR/ESR spectroscopy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">release behavior</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">disulfide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">conjugate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">albumin binding moieties</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">peptides</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Evans blue</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">butyric acid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">integrin αvβ6</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">integrin αvβ6 binding peptide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">improved pharmacokinetics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PET imaging</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Albumine</subfield><subfield code="0">(DE-588)4001090-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Wirkstofffreisetzung</subfield><subfield code="0">(DE-588)4190018-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Therapeutisches System</subfield><subfield code="0">(DE-588)4267580-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Katona, Gábor</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-3-0365-4108-2</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://directory.doabooks.org/handle/20.500.12854/84432</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/books978-3-0365-4107-5</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-94-OAB</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033826048</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV048447842 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T20:29:45Z |
| indexdate | 2025-01-23T23:02:52Z |
| institution | BVB |
| isbn | 9783036541075 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033826048 |
| oclc_num | 1344241051 |
| open_access_boolean | 1 |
| owner | DE-12 DE-210 DE-521 DE-1102 DE-1046 DE-1028 DE-1050 DE-573 DE-M347 DE-92 DE-1051 DE-898 DE-BY-UBR DE-859 DE-860 DE-1049 DE-861 DE-863 DE-BY-FWS DE-862 DE-BY-FWS DE-Re13 DE-BY-UBR DE-Y3 DE-255 DE-Y7 DE-Y2 DE-70 DE-2174 DE-127 DE-22 DE-BY-UBG DE-155 DE-BY-UBR DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-703 DE-20 DE-706 DE-824 DE-29 DE-739 |
| owner_facet | DE-12 DE-210 DE-521 DE-1102 DE-1046 DE-1028 DE-1050 DE-573 DE-M347 DE-92 DE-1051 DE-898 DE-BY-UBR DE-859 DE-860 DE-1049 DE-861 DE-863 DE-BY-FWS DE-862 DE-BY-FWS DE-Re13 DE-BY-UBR DE-Y3 DE-255 DE-Y7 DE-Y2 DE-70 DE-2174 DE-127 DE-22 DE-BY-UBG DE-155 DE-BY-UBR DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-703 DE-20 DE-706 DE-824 DE-29 DE-739 |
| physical | 1 Online-Ressource (ix, 149 Seiten) |
| psigel | ZDB-94-OAB |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | marc |
| spelling | Albumin-based drug delivery systems editor Gáabor Katona Basel MDPI - Multidisciplinary Digital Publishing Institute [2022] The Hague OAPEN FOUNDATION © 2022 1 Online-Ressource (ix, 149 Seiten) txt rdacontent c rdamedia cr rdacarrier Titelrückseite: This is a reprint of articles from the Special Issue published online in the open access journal Pharmaceutics (ISSN 1999-4923) (available at: www.mdpi.com/journal/pharmaceutics/special_issues/albumin_DDS). Albumin is playing an increasing role as a versatile, biodegradable drug carrier in clinical theranostics. By applying different techniques, smart drug-delivery systems can be developed from albumin in order to improve drug delivery of different active pharmaceutical ingredients, even small-molecule drugs, peptides or enzymes. Principally, three drug delivery technologies can be distinguished for binding small-molecule or peptide drugs through the charged amino acids, carboxyl, and amino groups of albumin: physical or covalent binding of the drug to albumin through a ligand- or protein-binding group, the fusion of drug with albumin or the encapsulation of drugs into albumin nanoparticles. The accumulation of albumin in inflamed tissues and solid tumours forms the rationale for developing albumin-based drug delivery systems for targeted drug delivery. Besides tumour therapy, albumin-based drug delivery systems can be successfully applied as anti-inflammatory and anti-thrombotic coating for medical devices. The development and optimization of albumin nanoparticles may also be a rational and promising tool for conventional or alternative administration routes in order to improve therapy. This collection provides an overview of the significant scientific research works in this field, which may inspire researchers towards further development and utilization of these smart drug delivery systems. Albumine (DE-588)4001090-9 gnd rswk-swf Wirkstofffreisetzung (DE-588)4190018-2 gnd rswk-swf Therapeutisches System (DE-588)4267580-7 gnd rswk-swf plasma half-life extension albumin conjugation in vivo glucose-lowering activity glucagon-like peptide-1 quality by design rapid equilibrium dialysis muco-adhesion brain PAMPA RPMI 2650 nasal epithelial cell human serum albumin dimerization doxorubicin enhanced permeability and retention effect antitumor Arthrobacter globiformis gout half-life extension inverse electron demand Diels-Alder reaction site-specific albumin conjugation thermostability urate oxidase albumin anti-thrombotic CD39 coating of medical devices stent coating therapeutic fusion protein conjugates vanadium cancer prodrug hydrogels EPR/ESR spectroscopy release behavior disulfide glioma conjugate albumin binding moieties peptides Evans blue butyric acid integrin αvβ6 integrin αvβ6 binding peptide improved pharmacokinetics PET imaging (DE-588)4143413-4 Aufsatzsammlung gnd-content Albumine (DE-588)4001090-9 s Wirkstofffreisetzung (DE-588)4190018-2 s Therapeutisches System (DE-588)4267580-7 s DE-604 Katona, Gábor edt Erscheint auch als Druck-Ausgabe, Hardcover 978-3-0365-4108-2 https://directory.doabooks.org/handle/20.500.12854/84432 Verlag kostenfrei Volltext https://doi.org/10.3390/books978-3-0365-4107-5 Verlag kostenfrei Volltext |
| spellingShingle | Albumin-based drug delivery systems Albumine (DE-588)4001090-9 gnd Wirkstofffreisetzung (DE-588)4190018-2 gnd Therapeutisches System (DE-588)4267580-7 gnd |
| subject_GND | (DE-588)4001090-9 (DE-588)4190018-2 (DE-588)4267580-7 (DE-588)4143413-4 |
| title | Albumin-based drug delivery systems |
| title_auth | Albumin-based drug delivery systems |
| title_exact_search | Albumin-based drug delivery systems |
| title_exact_search_txtP | Albumin-based drug delivery systems |
| title_full | Albumin-based drug delivery systems editor Gáabor Katona |
| title_fullStr | Albumin-based drug delivery systems editor Gáabor Katona |
| title_full_unstemmed | Albumin-based drug delivery systems editor Gáabor Katona |
| title_short | Albumin-based drug delivery systems |
| title_sort | albumin based drug delivery systems |
| topic | Albumine (DE-588)4001090-9 gnd Wirkstofffreisetzung (DE-588)4190018-2 gnd Therapeutisches System (DE-588)4267580-7 gnd |
| topic_facet | Albumine Wirkstofffreisetzung Therapeutisches System Aufsatzsammlung |
| url | https://directory.doabooks.org/handle/20.500.12854/84432 https://doi.org/10.3390/books978-3-0365-4107-5 |
| work_keys_str_mv | AT katonagabor albuminbaseddrugdeliverysystems |